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Feline immunodeficiency virus (FIV) shares remarkable homology to primate lentiviruses, human immunodeficiency virus (HIV) and
simian immunodeficiency virus (SIV). The process of lentiviral env glycoprotein-mediated fusion of membranes is essential for viral entry
and syncytia formation. A detailed understanding of this phenomenon has helped identify new targets for antiviral drug development. Using a
model based on syncytia formation between FIV env-expressing cells and a feline CD4+ T cell line we have studied the mechanism of FIV
env-mediated fusion. Using this model we show that FIV env-mediated fusion mechanism and kinetics are similar to HIV env. Syncytia
formation could be blocked by CXCR4 antagonist AMD3100, establishing the importance of this receptor in FIV gp120 binding.
Interestingly, CXCR4 alone was not sufficient to allow fusion by a primary isolate of FIV, as env glycoprotein from FIV-NCSU1 failed to
induce syncytia in several feline cell lines expressing CXCR4. Syncytia formation could be inhibited at a post-CXCR4 binding step by
synthetic peptide T1971, which inhibits interaction of heptad repeat regions of gp41 and formation of the hairpin structure. Finally, using site-
directed mutagenesis, we also show that a conserved tryptophan-rich region in the membrane proximal ectodomain of gp41 is critical for
fusion, possibly at steps post hairpin structure formation.
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Feline immunodeficiency virus (FIV) (Pedersen et al.,
1987) and human immunodeficiency virus (HIV) are
lentiviruses that share significant homology in their ge-
nomic organization and cause remarkably similar disease
in their respective hosts. Both infections are characterized
by a progressive depletion of CD4+ T cells leading to
immunodeficiency. The mechanism(s) mediating CD4+ T
cell loss has yet to be elucidated, but productive infection
does not appear to be the only cause (Alimonti et al.,
2003). Among other proposed mechanisms, env-mediated
cell fusion and death have been implicated in CD4+ T cell
depletion (Ferri et al., 2000). Enveloped viruses like HIV
and FIV utilize the env glycoprotein on their surface to0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: Wayne_Tompkins@ncsu.edu (W.A.F. Tompkins).mediate fusion between viral and cellular membranes. This
process is critical for viral entry and infection, and also
results in the formation of syncytia that is often seen in
vitro (Ferri et al., 2000). Models exploiting the potential of
HIV env glycoprotein to mediate syncytia formation have
been used to study the interaction between env glycopro-
tein and cell surface receptors on target cells (Gallo et al.,
2003; Jones et al., 1998), kinetics of env-mediated fusion
(Reeves et al., 2002), molecular determinants of the
fusogenic property of env glycoprotein (Salzwedel et al.,
1999), as well as designing and testing various inhibitors
of viral entry (Lawless et al., 1996).
The process of env-mediated fusion itself is complex,
involving several receptor ligand interactions and confor-
mational changes in the env glycoprotein. HIV env glyco-
protein is synthesized as a gp160 precursor and later
proteolytically cleaved to the gp120 surface unit and the
gp41 transmembrane protein (Chen, 1996; Wyatt and
Sodroski, 1998). Gp120 and gp41 are held together by
non-covalent interactions, and the presence of both proteins
is required to mediate fusion (Salzwedel et al., 1993). HIV
gp120 binds CD4 and a chemokine receptor, CCR5 or
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while gp41 mediates fusion (Hart et al., 1991). HIV env-
mediated fusion has been studied extensively, and various
steps involved in this process have been identified (Gallo
et al., 2003). The fusion process is initiated when gp120
binds CD4 resulting in a conformational change in gp120
that allows co-receptor (CCR5/CXCR4) binding. Subse-
quent conformational changes in gp120 allow insertion of
the hydrophobic fusion domain of gp41 into the target
cell and exposure of the heptad repeat-1 (HR1) and
heptad repeat-2 (HR2) coiled domains of gp41 (Jones
et al., 1998). The gp41 molecule on the membrane
surface forms highly stable trimeric complexes of HR1
and HR2 running in antiparallel fashion (Lu et al., 1995).
An interesting phenomenon first reported for influenza
virus (Carr and Kim, 1993) is the interaction of trimeric
HR1 and HR2 coiled domains in a zipper-like fashion
(Wild et al., 1994b) to form the hairpin structure or the
six-helix bundle that brings the viral and cell membrane
into close contact resulting in fusion. This phenomenon
remains true for a variety of enveloped viruses including
HIV (Melikyan et al., 2000) and FIV (Medinas et al.,
2002). The importance of this coiling event in the
infection process is underscored by the recent demonstra-
tion that peptides corresponding to the HR1 and HR2
coiled domains are potent inhibitors of HIV env-mediated
fusion (Kilby et al., 1998; Wild et al., 1994a). Similar
peptides capable of inhibiting FIV fusion and entry have
been identified for FIV (Medinas et al., 2002).
Although a detailed understanding of HIV env-mediat-
ed fusion has been established, certain aspects of this
process such as the events post hairpin structure formation
are not clearly defined. In this context, a region of HIV
gp41 corresponding to the membrane proximal ectodo-
main also called the pre-transmembrane region (pre-TM)
has gained importance in the fusion process. This region
is known to contain highly conserved tryptophans in
various lentiviruses including FIV. Mutational analysis
shows that tryptophans in the pre-TM region are criticalFig. 1. Schematic diagram of FIV gene orientation and primers used for clonin
rev (pFIVenv/rev) was cloned into pcDNA3 vector under the control of the
site and reverse primers (primers 2 and 3) had an EcoR1 overhang. The
pcDNA3 vector.for HIV env-mediated fusion (Salzwedel et al., 1999),
suggesting that it may be a second fusion domain in HIV
(Suarez et al., 2000) and play a critical role in env-
mediated fusion at a post hairpin structure stage (Saez-
Cirion et al., 2002). In support of this, Giannecchini et al.
(2003) recently identified an octapeptide spanning the pre-
TM region in FIV that has anti-viral activity, most likely
by inhibiting fusion.
Although it has been shown that FIV env does not bind
CD4 (Hosie et al., 1993; Willett et al., 1997), an interesting
finding is that FIV and HIV share the chemokine receptor
CXCR4 for viral entry and syncytia formation (Richardson
et al., 1999). The laboratory-adapted Petaluma strain of FIV
(FIV-pet) can utilize either feline or human CXCR4 for
mediating fusion (Willett et al., 1997). Based on this,
several previous studies (Medinas et al., 2002; Willett et
al., 1998) have utilized Crandell feline kidney (CrFK) cells,
chronically infected FIV-pet (CrFKpet), and CXCR4
expressing HeLa cells as a model for studying FIV env-
mediated fusion. As most primary isolates of FIV do not
infect CrFK cells, the ability of FIV env from various
isolates to use CXCR4 as a receptor for viral entry or
syncytia formation remains controversial. Although it is
widely accepted that the laboratory adapted FIV-pet utilizes
CXCR4 to induce fusion in a variety of cells, including the
human cell line HeLa, the results with other primary
isolates have been varied (De Parseval and Elder, 2001;
Willett et al., 2002), suggesting the requirement of yet to be
identified receptor–co-receptor.
The objective of the present study was to develop a
suitable model to study FIV env-mediated fusion by a
primary isolate of FIV in lymphocytic target cell lines. For
this purpose we have cloned and expressed the env glyco-
protein from a primary isolate of FIV (FIV-NCSU1) in CrFK
cells. Cells expressing env glycoprotein from FIV-NCSU1
(CrFKenv/rev) showed fusion with the IL-2-dependent
feline T cell line FCD4E cells. Using a quantitative assay
based on syncytia formation between CrFKenv/rev cells and
FCD4E cells, we were able to block env-mediated fusion atg FIV env. FIV env gene either alone (pFIVenv) or in combination with
CMV promoter. The forward primer (primer1) had a BamH1 overhang
PCR products were directionally cloned into BamH1 EcoR1-digested
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changes, and demonstrated the role of CXCR4, gp41-coiled
domains, and conserved tryptophan-rich regions of gp41 in
FIV env-mediated fusion. This simple model can be used to
address numerous questions concerning FIV env interac-
tions with cell surface receptors on T cells and their role in
FIV cell entry and pathogenesis.Results
FIV env gene expression is rev dependent
To study the role of env glycoprotein in FIV pathogen-
esis, we cloned and expressed the env gene from the
pathogenic NCSU1 primary isolate of FIV (Yang et al.,
1996). The expression of retroviral genes is complex andFig. 2. Expression of FIV env glycoprotein in transfected cells. (A)
Western blot showing FIV env expression. Total cellular extracts from
transfected CrFK cells were run on SDS page gel, blotted onto PVDF
membrane, and probed with SU1–30 mAb against FIV gp120, which also
reacts with unprocessed gp160 protein. Lane 1: CrFK infected with
Petaluma strain of FIV; lane 2: CrFK transfected with pFIVenv/rev; lane 3:
CrFK transfected with pFIVenv; lane 4: CrFK non-transfected. (B)
Immunocytochemistry of transfected CrFK cells using serum from an
FIV-infected cat. CrFK cells were transfected with either pFIVenv or
pFIVenv/rev and selected for neomycin resistance. Selected cells were
stained with serum from FIV+ cat followed by HRP-conjugated anti-cat
antibody and developed with AEC substrate.
Fig. 3. Membrane-expressed FIV env induces syncytia formation with
FCD4E cells. (A) FIV env-expressing CrFK (CrFKenv/rev) cells were co-
cultured with the feline CD4+ T cell line (FCD4E). At 24 h post co-culture,
the plates were fixed and stained with Geimsa stain. (B) Two-color
fluorescent dye redistribution assay showing FIV env-mediated fusion
between CMFDA-labeled CrFKenv/rev cells and CMTMR-labeled FCD4E
cells. Labeled cells were co-cultured for 24 h, following which plates were
fixed with 3.7% paraformaldehyde and analyzed by fluorescent microsco-
py. Fused syncytial plaques (indicated by arrows) are positive for both dyes.
(C) Fusion mediated by in vitro-expressed FIV env is linearly related to the
number of target cells (FCD4E) added. CrFKenv/rev cells at 2  104 cells/
well were co-cultured with FCD4E cells at 2-fold serial dilutions starting at
104 cells/well. Fusion was quantified by counting the number of syncytial
plaques formed per well 24 h post co-culture. Data are mean F standard
deviation of quadruplicate wells.involves multiple splicing of viral RNA. Rev, a regulatory
protein, reported in both HIV and FIV has been shown to
function as a transporter of full-length and partially spliced
HIV RNA out of the nucleus (Hadzopoulou-Cladaras et al.,
1989; Hammarskjold et al., 1989; Phillips et al., 1992). To
determine a similar function of rev in FIV we developed
two clones, one containing the open reading frame (orf) of
the env gene alone (pFIVenv) and other included the env
gene along with the 3Vexon of the rev gene (pFIVenv/rev)
(Fig. 1). Transfection of CrFK cells with these constructs
revealed that expression of FIV env as determined by
Western blotting and immunocytochemistry could be
achieved with the pFIVenv/rev construct but not with
Fig. 4. FIV env-mediated fusion can be blocked at the level of the env
glycoprotein. (A) CrFKenv/rev cells were co-cultured with FCD4E cells.
Serum from FIV+ or FIV cats was added 1 h before co-culture. Fusion
was measured 24 h later and expressed as percent control (no treatment).
Data are mean F standard deviation. (B) CrFKenv/rev cells were seeded in
96-well plates at 2  104 cells/well. FCD4E cells were added at 5  103/
well. Fusion inhibitor T1971 or control peptide T1566 with no inhibitory
activity was added in serial 2-fold dilutions 1 h before co-culture. Fusion
was estimated 24 h later as described above. Data are mean F standard
deviation of quadruplicate wells.
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detected in both pFIVenv- and pFIVenv/rev-transfected cells
by RT-PCR (data not shown), suggesting that the role of rev
in env gene expression is at a posttranscriptional level. The
requirement of rev is absolutely critical for FIV env expres-
sion, and this simple mechanism of providing rev from the
same plasmid can be used for efficient expression of FIV
env from eukaryotic expression vectors. Using this con-
struct we established a stable cell line expressing FIV-
NCSU1 env termed CrFKenv/rev that was used in all
subsequent studies.
Membrane expressed env glycoprotein causes syncytia
formation with a feline CD4+ T cell line
To assess the biological activity of the expressed env
glycoprotein, a fusion assay was developed using env-
expressing CrFKenv/rev cells and the IL-2-dependent feline
CD4+ T cell line (FCD4E). Co-culture of CrFKenv/rev
cells with FCD4E cells resulted in the formation of syncy-
tia (Fig. 3A). To confirm that the syncytia seen in the co-
culture were formed due to fusion between CrFKenv/rev
(effector) cells and FCD4E (target) cells, a two-color
fluorescent dye redistribution assay was performed. Co-
culture of differentially labeled effector and target cells
resulted in the formation of syncytial plaques that were
double positive for the fluorescent dyes, indicating that the
fusion was in fact between effector and target cell (Fig.
3B). For most other experiments, the non-fluorescent syn-
cytial plaque-forming assay was used. A two-fold serial
dilution of target cells in the assay showed a linear
relationship between the number of target cells added and
number of syncytia formed (Fig. 3C). Based on this
experiment, 5–2.5  103 target cells/well gave the most
reproducible results.
Blocking of FIV env-mediated fusion
To validate the specificity of env-mediated fusion, either
pooled serum from FIV-infected cats (FIV+ serum) or gp41-
specific fusion inhibitor T1971 was incorporated in the
assay as possible blocking agents. FIV+ serum (shown to
have antibodies to FIV env by immunocytochemistry in Fig.
2B) blocked env-mediated fusion in a dose-dependent
manner (Fig. 4A). The fusion event mediated by HIV and
FIV env involves interaction among coiled domains of gp41
at a post gp120 binding stage. Peptides corresponding to the
coiled domains of HIV and FIV gp41 have been shown to
be potent inhibitors of env-mediated fusion (Kilby et al.,
1998; Medinas et al., 2002). One of these inhibitors, T1971,
shown to have significant fusion inhibition against FIV in
an earlier study (Medinas et al., 2002) blocked syncytia
formation in the CrFKenv/rev-FCD4E syncytia forming
assay in a dose-dependent manner, while T1566, a peptide
derived from a region outside the coiled domains of FIV
gp41, had no inhibitory activity (Fig. 4B). This studyconfirmed the biological activity and specificity of the
cloned env glycoprotein.
CXCR4 is involved in FIV env-mediated fusion of FCD4E
cells
It has been reported that FIV utilizes CXCR4 as a
receptor for viral entry and cell fusion (Hosie et al., 1998;
Willett et al., 1997). To determine if FIV-NCSU1 utilizes
CXCR4, antihuman CXCR4 antibodies were assessed for
their ability to block fusion. Antihuman CXCR4 monoclo-
nal antibodies (mAb) 12G5 and 44717 failed to block
CrFKenv/rev- or CrFKpet-induced fusion with FCD4E
(feline) cells up to a concentration of 30 Ag/ml, but
interestingly, both antibodies completely blocked fusion of
CrFKpet with HeLa (human) cells at 3 Ag/ml (data not
shown). Previous studies (Egberink et al., 1999; Hosie et al.,
1998) and our own observation demonstrated that mAb
44717 cross-reacts with feline CXCR4, whereas 12G5 fails
to bind feline cells. We confirmed these findings by flow
cytometric analysis of FCD4E cells (data not shown).
Failure of cross-reacting mAb 44717 to block fusion medi-
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adapted FIV-pet strain in feline cells may be due to weak
binding affinity or more likely due to failure to mask the
FIV env-binding site on the feline CXCR4 receptor. This is
supported by our observation that fusion mediated via feline
CXCR4 (by either NCSU1 or Petaluma) could not be
inhibited up to a concentration of 30 Ag/ml of mAb 44717
while the cell surface staining of feline cells was saturated at
5 Ag/ml. Also, fusion via human CXCR4 (CrFKpet-HeLa
model) was completely inhibited at 10-fold lower concen-
tration of 3 Ag/ml (data not shown).
To further explore a role for CXCR4 in FIV env-medi-
ated fusion, the CXCR4 antagonist AMD3100 that has been
shown to block infection of feline cells by various isolates
of FIV (Egberink et al., 1999) was used in the fusion assay.
Interestingly, AMD3100 efficiently blocked syncytia forma-
tion between FIV-NSCU1 env-expressing CrFKenv/rev cells
and FCD4E cells in a dose-dependent manner (Fig. 5A). To
determine that AMD3100 was in fact binding to feline
CXCR4, a competitive assay was done to block binding
of cross-reacting anti-CXCR4 mAb 44717 to FCD4E cells
by excess of AMD 3100 and analyzed by flow cytometry.
AMD3100 at 1 AM completely blocked binding of mAb
44717 to FCD4E cells (Fig. 5B). These results are in
accordance with previous reports of FIV env binding toFig. 5. CXCR4 is involved in FIV env-mediated cell fusion. (A) CrFKenv/rev cell
AMD3100 added at the indicated concentration 1 h before co-culture. The cells
analyzed for syncytia formation. Data are mean F standard deviation of quadrup
FCD4E cells. FCD4E cells were stained with either isotype control or anti-CXCR4
by flow cytometry.CXCR4 and confirm that feline CXCR4 is involved in
binding and fusion mediated by FIV-NCSU1 env.
CXCR4 is required but not sufficient for fusion by a primary
isolate (NCSU1) of FIV
Having established that CXCR4 was involved in bind-
ing and fusion between CrFKenv/rev cells and FCD4E
cells, we assessed the ability of FIV-NCSU1 env to induce
syncytia formation with other CXCR4 expressing feline or
human cell lines. We tested FCD4E (CD4+ feline T cell
line), Fet J cells (CD8+ feline T cell line), 3201 cells
(CD4+CD8+ feline lymphoma cell line), and HeLa cells
(human epithelial cell line), all of which express CXCR4
on their surface, for their ability to fuse with CrFK cells
expressing either the FIV-NCSU1 env (CrFKenv/rev) or
chronically infected with FIV-pet (CrFKpet). Interestingly,
only FCD4E cells fused with CrFKenv/rev cells, while all
four cell lines fused with CrFKpet cells (Figs. 6A and 6B).
These results are consistent with the observation that of all
the cell lines tested, FIV-NCSU1 is capable of infecting
only FCD4E cells, whereas the cell culture-adapted FIV-
pet isolate has a wider tropism (Verschoor et al., 1995).
FACS analysis of CXCR4 expression revealed that FCD4E
cells, the only cell line capable of fusion with FIV-NCSU1s were co-cultured with FCD4E cells in the presence of CXCR4 antagonist
were co-cultured for 24 h following which plates were fixed, stained, and
licate wells. (B) AMD3100 blocks binding of anti-CXCR4 mAb 44717 to
antibody 44717 in the presence or absence of 1 AMAMD3100 and analyzed
Fig. 6. CXCR4 is required but not sufficient to mediate fusion by primary isolate of FIV. Cells either expressing FIV-NCSU1 env (CrFKenv/rev) or infected
with FIV-pet (CrFKpet) were tested for their potential to fuse with various cell lines in a co-culture assay as described in Materials and methods. CrFKenv/rev
(A) or CrFKpet (B) cells were seeded at 5  104 cells/well; FCD4E, 3201, and Fet-J cells were added at 2-fold serial dilution starting at 104 cells/well and
incubated for 24 h following which the plates were fixed, stained, and photographed. For fusion with HeLa cells, HeLa cells were seeded at 104 cells followed
by 5  102 CrFKenv/rev or CrFKpet. Either 104 or 5  103 dilution wells shown for Fet-J, 3201, and FCD4E. (C) Flow cytometric analysis of CXCR4
expression on various cells lines. Cells were incubated with antihuman CXCR4 Ab 44717 or isotype control followed by FITC-conjugated secondary Ab and
analyzed by flow cytometry.
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Fig. 7. Time dependent inhibition of fusion by AMD3100 and T1971.
CrFKenv/rev cells were co-cultured with FCD4E cells as described in
Materials and methods. Inhibitors AMD3100 at 1 AM and T197 at 0.3 AM
were added at the indicated time points post cell mixing starting at 0 h.
After a total incubation of 24 h, the plates were fixed and the number of
syncytial plaques counted. Data are mean F standard deviation of
quadruplicate wells (*P < 0.01 refers to comparison between AMD3100
and T1971).
Fig. 6 (continued).
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ing that the level of CXCR4 expression was not a limiting
factor in FIV-NCSU1 env-mediated fusion. These findings
suggest that in contrast to the cell culture-adapted FIV-pet
isolate, the primary FIV isolate NCSU1 may utilize a
receptor–co-receptor in addition to CXCR4 for cell entry
and fusion, as has been suggested for other primary
isolates (De Parseval and Elder, 2001).
FIV env-mediated fusion is rapid and follows kinetics
similar to HIV env glycoprotein
To determine if the fusion process mediated by FIV env
follows similar kinetics as HIV env-mediated fusion, either
T1971 or AMD3100 was added at different time points post
co-culture. As shown in Fig. 7, the fusion process could be
completely blocked when T1971 or AMD3100 was added
up to 45 min post co-culture. At time points 1.5 and 2 h,
AMD3100 was significantly less effective at blocking
syncytia formation than T1971 (P < 0.01), suggesting that
T1971 acts at time points post CXCR4 binding. Our data
indicate that while some of the cells have completed fusion
as early as 1 h, it takes up to 4 h for all cells to complete
fusion under our assay conditions. The kinetics of fusion in
the presence of AMD3100 or T1971 were similar, suggest-ing that the limiting factor in FIV env-mediated fusion was
gp120 binding to receptor–co-receptor and not gp41 hairpin
structure formation, which was rapid after CXCR4 engage-
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(Gallo et al., 2001).
Conserved tryptophans in the pre-transmembrane region of
FIV gp41 are essential for fusion
Sequence analysis of HIV and FIV env glycoproteins
revealed significant homology in the gp41 region and not in
the gp120 region. A region of HIV gp41 N terminal to theFig. 8. The conserved tryptophan-rich region in gp41 is critical for fusion. (A) Schem
that is conserved in various lentiviruses and among various isolates of FIV. (B) Exp
which all three tryptophanswere replaced by alanine. CrFK cells were transiently tran
by Western blotting and fusion by a co-culture assay as described above.membrane-spanning region called the pre-TM region has
been shown to have conserved tryptophans (W) that are
critical for membrane fusion (Salzwedel et al., 1999). Based
on the observation that the pre-TM region of FIV gp41 also
has conserved tryptophans (Fig. 8A), we used site-directed
mutagenesis to replace W at positions 766, 769, and 772
with Alanine (A). The mutant env/rev construct thus gen-
erated [W(1–3)A] was transfected into CrFK cells and
tested for its fusion-inducing ability with FCD4E cells. Asatic diagram of FIV gp41 showing the location of the tryptophan-rich region
ression and fusion potential of wild-type (WT) and mutant env W(1–3)A in
sfectedwithWTorW(1–3)A env constructs and analyzed for env expression
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of expression and processing as the wild type (WT), but was
completely defective in forming syncytia with FCD4E cells.
As with HIV, this region appears to be critical for fusion by
FIV env and that the presence of tryptophans is required for
this property.Discussion
The present study was undertaken to develop an in vitro
model to study interactions of membrane-expressed FIV env
with receptors on T cells that leads to env-mediated fusion.
We have used this model to study env receptor interactions
as well as kinetic analysis of FIV env-mediated fusion.
Several critical questions regarding FIV env expression
and function are answered in our study. Firstly, failure to
express FIVenv from a plasmid lacking 3Vrev-coding region
suggests that the expression of FIV env, similar to HIV env,
is rev dependent. Rev is involved in the transport of
unspliced and partially spliced env mRNA from the nucleus
(Malim et al., 1989). Similar constructs have been used to
express HIV env glycoprotein in transfected cells (Ham-
marskjold et al., 1989). In some studies with HIV, rev has
been provided in trans from another plasmid to obtain env
expression (Moir and Poulin, 1996). In our system, provid-
ingly rev from the same plasmid is sufficient to get efficient
express env. Using this construct we were able to study the
various steps involved in FIV env-mediated fusion and
correlate it to findings with HIV.
The first step in HIV env-mediated fusion is the binding
of gp120 to CD4 and CXCR4 on T cells (Choe et al.,
1998). Although several studies have ruled out a role of
CD4 as a receptor for FIV (Hosie et al., 1993; Willett et al.,
1997), CXCR4 has been well established as a necessary
receptor or co-receptor for the laboratory-adapted Petaluma
isolate of FIV (Hosie et al., 1998; Richardson et al., 1999),
while results with primary isolates have been varied. In
support of this, a recent report by Willett et al. (2002)
shows that expression of feline CXCR4 alone was sufficient
for viral entry and fusion by laboratory-adapted FIV-pet,
but not the primary isolate FIV-Glasgow. Similarly, studies
by De Parseval and Elder (2001) have shown a yet
unidentified 40-kDa protein on T cells that bind recombi-
nant FIV gp120 from the primary isolate FIV-PPR. In the
same study, CXCR4 agonist SDF-1 failed to inhibit recom-
binant FIV-PPR gp120 binding to T cells. In both these
studies, the authors fail to show direct evidence that the env
glycoprotein from primary isolates bind to or utilize feline
CXCR4. Using CXCR4 antagonist AMD3100 we show
that CXCR4 is in fact a receptor (co-receptor) for FIV-
NCSU1 and plays a necessary role in FIV env-mediated cell
fusion by both primary- and laboratory-adapted strains of
FIV. Cross-reacting antihuman CXCR4 antibody failed to
block fusion in our model even though excess AMD3100
blocked binding of this antibody to FCD4E cells. Webelieve that the failure to inhibit fusion via cross reacting
antibody is likely due to failure to mask the FIV env-
binding site on feline cells. This is supported by the report
of Willett et al. (1998) showing that the second extracellular
loop of CXCR4 that is required for FIV env binding
contains the majority of differences between feline and
human CXCR4.
Primary isolates of FIV, including NCSU1, neither infect
nor mediate fusion in CXCR4-expressing CrFK cells (Hoh-
datsu et al., 1996), which suggests that a second receptor
may be required for entry by these viruses. The differences
between FIV-pet and primary isolates have been largely
attributed to variation in the env gene sequence, more
specifically changes in the V3 loop of FIV-pet resulting in
a net positive charge in this region have been implicated in
the broader tropism and fusogenicity of FIV-Pet (Verschoor
et al., 1995). We show that while CrFK cells infected with
FIV-pet (CrFKpet) would fuse with a variety of cell lines
expressing CXCR4, such as Fet J, 3201, HeLa, and FCD4E
cells, cells expressing FIV-NCSU1 env (CrFKenv/rev) fused
only with FCD4E cells. This is again in agreement with the
tropism of NCSU1, which productively infects only FCD4E
cells or primary lymphocytes (English et al., 1993). This
suggests that though CXCR4 is required, it is not sufficient
for fusion by primary isolates of FIV and that another
receptor or co-receptor expressed on FCD4E cells may be
involved. Although FCD4E cells express CD4, it is not a
receptor for FIV as has been shown previously (Hosie et al.,
1993). Our findings confirm that FIV-NCSU1 binds feline
CXCR4, but expression of CXCR4 alone was not sufficient
to induce fusion and that another receptor–co-receptor may
be involved.
Following HIV gp120 binding to CD4/CXCR4, a con-
formational change in the env glycoprotein occurs that
results in insertion of the N terminal fusion domain of
gp41 into the target cell membrane and exposure of the
coiled domains HR-1 and HR-2 of gp41 (Wild et al.,
1994b). Interaction among the coiled domains of gp41 in
a zipper-like fashion (Wild et al., 1994b) brings the mem-
branes close together facilitating fusion. Lentiviral env
glycoprotein is present as a trimer on the membrane surface,
and hence interaction of the coiled domains results in
formation of a six-helix bundle structure. Peptides corr-
esponding to either the HR-1- or HR-2-coiled domains of
HIVor FIV gp41 have the unique property of inhibiting six-
helix bundle formation and thus viral entry (Wild et al.,
1994a). These peptides have evolved into a new generation
of anti-HIV drugs premiered by T-20 (Enfuvirtide) (Moyle,
2003). Gp41-specific peptide inhibitors are also powerful
tools to study env interactions post receptor–co-receptor
binding. We utilized an FIV-specific fusion inhibitor T1971,
previously shown to block CrFKpet fusion with HeLa cells
(Medinas et al., 2002), to block fusion in our model in a
dose-dependent manner. Inhibition by gp41-specific fusion
inhibitors is unique because it inhibits env response at a
post-CXCR4 binding stage (Gallo et al., 2001).
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cific fusion inhibitor T1971, we studied the kinetics of FIV-
NCSU-1 env-mediated fusion by inhibiting this process at
different time points post co-culture. As shown in Fig. 7, we
see a lag phase of around 45 min in fusion mediated by FIV-
NCSU1, which is not too different from 20 to 30 min
reported for HIV (Melikyan et al., 2000). T1971 was more
efficient than AMD3100 at inhibiting fusion at time points
1.5 and 2 h. This correlates with the proposed sequence of
events involved in env-mediated fusion in that CXCR4
binding precedes and induces gp41 hairpin formation.
Nevertheless, the overall kinetics of fusion in the presence
of T1971 or AMD 3100 were similar, suggesting that the
limiting factor in FIV env-mediated fusion is not gp41
hairpin structure formation, which probably occurs rapidly
after receptor–co-receptor binding.
The events after hairpin formation that may be important
for fusion in HIV have not been well characterized. However,
a tryptophan-rich region of gp41 proximal to the membrane-
spanning domain termed pre-transmembrane region has
gained importance following a report by Salzwedel et al.
(1999) that conserved tryptophans in this region are critical
for fusion. Further, others have shown that this region is a
novel fusogenic domain (Suarez et al., 2000) and that it has
lectin-like properties and binds to sphingomyelin- and cho-
lesterol-rich structures in cell membranes (Saez-Cirion et al.,
2002). Sequence analysis showed that tryptophans in this
region were conserved among various lentiviruses and also
within various strains of FIV (Fig. 8A). We used site-directed
mutagenesis to replace tryptophans (W) in this region with
alanine (A) resulting in a fusion-defective mutant. We hy-
pothesize that the hydrophobic nature ofW in this region may
facilitate fusion at a step post six-helix bundle formation byFig. 9. Proposed sequence of events leading to FIV env-mediated fusion. Step1
receptor–co-receptor on the surface of target cells. Step 2: a conformational change
target membrane and exposure of the coiled domain. Step 3: the coiled domains int
4: the pre-TM region of gp41 may mediate mixing of the lipid components of the
unable to mediate fusion].mediating mixing of lipid components of effector and target
membranes. Interestingly, Giannecchini et al. (2003) have
recently reported that an octapeptide spanning this region has
anti-FIV activity by inhibiting virus entry. The authors have
suggested that the peptide inhibits viral entry by binding to
components on the cell surface rather than any region in the
viral gp41 protein. They also found that tryptophans were
critical for the inhibitory activity of the peptides.
Using the CrFKenv/rev-FCD4E syncytia model, we have
delineated various steps that are involved in cell fusion and
syncytia formation by the env glycoprotein from FIV-
NCSU1 primary isolate (Fig. 9). The first step involves
gp120 binding to CXCR4 and possibly another receptor–
co-receptor on the cell surface. This is followed by confor-
mational changes in the env protein that result in exposure
of gp41 heptad repeat domains and six-helix bundle forma-
tion. Finally, our data indicate that the tryptophan-rich pre-
TM region has a critical role in FIV env-mediated fusion
probably at a step post six-helix bundle formation.Materials and methods
Antibodies and reagents
Antihuman CXCR4 antibodies 12G5 and 44717 were
obtained from BD Biosciences (San Jose, CA). Anti-FIV
gp120 antibody SU1–30 was obtained from Custom Mono-
clonals (West Sacramento, CA). Gp41 fusion inhibitor
T1971 and control peptide T1566 were a kind gift from
Robyn Medinas (Trimeris Inc., Durham, NC). CXCR4
antagonist AMD3100 was a kind gift from Dr Edward
Hoover, (Colorado State University).: FIV gp120 binds to CXCR4 (inhibited by AMD3100) and an unknown
in the env glycoprotein allows insertion of gp41 hydrophobic domain in the
eract with each other (inhibited by T1971) to form the hairpin structure. Step
effector and target membranes resulting in fusion [the W(1–3)A mutant is
logy 3Cell lines and cell culture
The CrFK or CrFKpet cell line (Crandell feline kidney
cells persistently infected with a CrFK-adapted strain of FIV-
Petaluma; stock number ATCC-CCL-94; American Type
Culture Collection [ATCC]) was maintained in Dulbecco’s
modification of Eagle’s medium (high glucose; Mediatech,
Herndon, VA) supplemented with 10% fetal bovine serum
(FBS) (Hyclone, Logan, UT), streptomycin (100 Ag/ml),
penicillin (100 IU/ml), L-glutamine (2 mM), HEPES (15
mM), and sodium pyruvate (2 mM) at 37 jC in 5% CO2.
The HeLa cell line (stock number ATCC-CCL-2; ATCC) was
maintained in DMEM (high glucose) supplemented as de-
scribed above. The feline T cell line (FCD4E) (an interleukin
2 [IL-2]-dependent feline CD4+ lymphocyte cell line de-
scribed by English et al., 1993) was maintained in RPMI
1640 medium (Mediatech) supplemented with 10% FBS,
streptomycin (100 Ag/ml), penicillin (100 IU/ml), L-gluta-
mine (2 mM), HEPES (15 mM), sodium pyruvate (2 mM), h-
mercaptoethanol (2.5  105 M), and recombinant human
IL-2 (rhIL-2) (100 U/ml; AIDS Reference and Reagent
Program) at 37 jC in 7% CO2. Other feline T cell lines Fet-
J and 3201 (Hohdatsu et al., 1996) were maintained as
described for FCD4E cells in the absence of IL-2.
Cloning of FIV env
Plasmid pFIVenv was generated by PCR amplification of
the env gene from a plasmid containing the molecular clone
JSY3 of FIV-NCSU1 (Yang et al., 1996) using primer
BamH1FIVenv> (ATTGGATCCGCAACAATAATTATGG-
CAGA) and <FIVenvEcoR1 (GCCGGAATTCAGTCTGA-
GATACTTCATCAT). For plasmid pFIVenv/rev, which
contained the 3V exon of rev, the forward primer was the
same as above (BamH1FIVenv>) and the reverse primer was
located at the end of the LTR region <FIVrevEcoR1
(ATAGAATTCAAGTTCTCGGCCCGGATTC) (underlined
sequences shows restriction enzyme sites). PCR-amplified
products were digested with BamH1 and EcoR1 and cloned
into BamH1- and EcoR1-digested pcDNA3 vector (Invitro-
gen). The cloned products were sequenced at the automated
DNA sequencing facility at University of North Carolina
(Chapel Hill, NC).
Transfection of cells
Subconfluent monolayers of CrFK cells were transfected
with 1 Ag of plasmid DNA of either pFIVenv or pFIVenv/
rev using Effectene transfection system (Qiagen Inc., Valen-
cia, CA) as per manufacturer’s instructions. Forty-eight
hours after transfection, the cells were seeded at low density
in selection medium containing G418 at 700 Ag/ml (Gib-
coBRL, Gaithersberg, MD). The cells were selected by
limiting dilution for at least 3 weeks before analysis and
use in experiments. Selected cells were maintained in 400
Ag/ml G418 throughout the study.
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Immunocytochemistry and Western blotting were used to
detect expression of FIV env in transfected cells. For
immunocytochemistry, transfected and selected CrFK cells
were seeded in 96-well plates and grown till subconfluent.
Cells were fixed with methanol 0.03% H2O2 for 30 min
followed by blocking with 0.1% bovine serum albumin
(BSA) in phosphate-buffered saline (PBS) for 1 h. Cells
were than stained with serum from an FIV-infected cat
diluted 1:1000 in blocking buffer (0.1% BSA in PBS) for
2 h. Subsequently, cells were stained with horseradish
peroxidase (HRP) conjugated goat anti-cat antibody (Cappel
Research products, Durham, NC) for 1 h. Finally, the plates
were developed with 3-amino-9-ethylcarbazole (AEC) sub-
strate kit (Biogenex, San Ramon, CA) and analyzed by
microscopy. For Western blotting, total cellular lysates were
run on a 4–12% polyacrylamide gel, transferred to PVDF
membrane, and blocked with Tris-buffered saline (TBS)
containing 0.05% Tween 20 with 1% gelatin, overnight.
Blocked membranes were blotted with monoclonal antibody
to FIV env, SU1–30, at 1 Ag/ml followed by HRP-conju-
gated goat anti-mouse antibody (Pierce Biotechnology Inc.,
Rockford, IL) at 0.1 Ag/ml in blocking buffer. The mem-
branes were developed with enhanced chemiluminescence
(ECL) system using ECL Western blotting kit (Pierce
Biotechnology Inc.). The developed membrane was ana-
lyzed by Lumimager (Boheringer, Germany).
FIV syncytial assay
The FIV syncytia forming assay utilized FCD4E cells and
CrFK cells transfected with pFIVenv/rev (CrFKenv/rev).
CrFKenv/rev cells were plated in a 96-well flat-bottom plates
at a concentration of 2  104 cells/well in 100 Al of DMEM
medium and allowed to adhere overnight. The following day,
the culture medium was aspirated and FCD4E cells, 5  103
in 100 Al of medium, were added to give reproducible
numbers of syncytia. After 24 h, the plates were fixed and
stained with crystal violet (stock stain: 2.5 g of crystal violet,
1.25 g of Giemsa stain, 500 ml of 80% methanol; working
solution: 200 ml of stock and 200 ml of 80% methanol).
Stained syncytial plaques (fused cells that are five cell
diameters or greater) were counted using an inverted micro-
scope. When the number of syncytia formed within 24 h was
compared to the number of FCD4E cells plated, there was a
linear correlation between the number of target cells plated
and the number of syncytia produced. For studies with CrFK
cells chronically infected with Petaluma strain of FIV (CrFK-
pet) and HeLa cells, the fusion assay used has been described
previously (Medinas et al., 2002). Briefly, HeLa cells were
plated at 104 cells/well in 96-well plates, and the following
day 5 102 CrFKpet cells were added. Plates were fixed and
stained the next day as described above. Various treatments
such as serum, peptides, or AMD3100 were added in a 2-fold
serial dilution series in 100 Al of FCD4E cell medium to the
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ment, the FCD4E or HeLa cells were pre-incubated with
serial dilutions of the Ab for 1 h before co-culture with CrFK
cells. For fusion assays with different feline cell lines, either
CrFKenv/rev or CrFKpet was seeded in 96-well plates at
2  104 cells/well. FCD4E, Fet-J, or 3201 was added 24
h later at 2-fold dilutions starting at 2  104 cells/well.
Plates were stained and observed for syncytia formation
24 h later as described above.
Flow cytometry
Different cell lines were stained with antihuman CXCR4
antibody 44717 that cross-reacts with feline CXCR4, fol-
lowed by FITC-conjugated goat anti-mouse IgG antibody
(BD Biosciences). Stained cells were analyzed by flow
cytometry using FACS Calibur (BD Biosciences). For inhi-
bition of anti-CXCR4 antibody binding to feline cells, feline
cells were incubated with either isotype control or 44717
antibody in the presence or absence of AMD3100 (0.5 Ag/
ml) for 1 h followed by washing and incubation with FITC-
conjugated goat anti-mouse antibody and analyzed as above.
Site directed mutagenesis
PCR-mediated site-directed mutagenesis was used to
induce a tryptophan (W) to alanine (A) mutation in the pre-
TM region of FIVenv. The following primer pairs were used
to generate two fragments: Fragment 1, BamH1FIVenv>
(sequence shown above) and <W(1 – 3)A-antisense
(CGCTCCTACCGCATCTTCCGCCTTTTGTAATT
GTTGTATCCC); Fragment 2, W(1–3)A-sense> (GCGGA-
AGATGCGGT AGGAGCGATAGGAAATATTCCACAA-
TAC) and <FIVrevEcoR1 (sequence shown above).
Fragments 1 and 2 were then used in an overlap PCR to ge-
nerate a mutant construct that was digested with EcoR1 and
BamH1 and cloned into pcDNA3 vector as described above.
The presence of mutation in the construct was confirmed by
sequencing.
Two-color fluorescent dye redistribution assay
For the two-color fluorescent dye redistribution assay,
CrFKenv/rev or CrFK control cells were labeled with
cytoplasmic dye 5-chloromethylfluorescein diacetate
(CMFDA) at a concentration of 0.5 Am in PBS for 30
min at 37 jC followed by washing twice with medium and
seeded in 96-well plates at 2  104 cells/well. The cells
were allowed to adhere overnight following which FCD4E
cells labeled with cytoplasmic dye 5- and 6-{[(4-choloro-
methyl) benzoyl] amino} tetramethyl rhodamine (CMTMR)
at a concentration of 5 Am were added to the wells at 5 
103/well. The cells were co-cultured for 24 h following
which the plates were washed to remove non-adherent cells
and fixed with 3.7% paraformaldehyde. Fixed plates were
analyzed by fluorescent microscope.Acknowledgments
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